Gainers Recap: Exelixis, Inc. (NASDAQ:EXEL), EverBank Financial Corp, Spreadtrum Communications, Chelsea Therapeutics International

Lakeway, NY -- (SBWIRE) -- 03/06/2013 -- ThePennyStockProfiler.com, an investment community with a special focus on updating investors with recent news on the U.S. stock market, issues news alert on the following stocks:-

Exelixis, Inc. (NASDAQ:EXEL) shares climbed 5.07% and closed at $4.77. The company, on Feb. 21, reported financial results for the fourth quarter and year ended December 31, 2012. Revenues for the quarter ended December 31, 2012 were $7.8 million, compared to $93.3 million for the comparable period in 2011. Net (loss) income for the quarter ended December 31, 2012 was ($52.2) million, or ($0.28) per share, compared to $46.3 million, or $0.35 per share, basic, for the comparable period in 2011.

How Should Investors Trade EXEL After The Recent Price movement? Find out Here

EverBank Financial Corp (NYSE:EVER) shares jumped 5.01% and closed at $16.14 in the last trading session. Bank of America reiterated EverBank Financial’s Buy rating yesterday and raised the price objective from $16.00 to $17.00. The company is an unitary savings and loan holding company. The Company provides a range of financial products and services directly to customers through multiple business channels.

Is EVER a Strong Buying Opportunity After The Recent Slump? Find out Here

Spreadtrum Communications, Inc (ADR) (NASDAQ:SPRD) shares increased 5.01% to $18.24. The company, on Feb. 26, announced that for first quarter of 2013, it expects revenue to be in the range of USD180 million to USD186 million, a sequential decrease of 8.4% to 11.4%. Analysts are expecting the company to report revenue of USD171 million for first quarter of 2013.

How Should Investors Trade SPRD After The Recent Price movement? Find out Here

Chelsea Therapeutics International Ltd.(NASDAQ:CHTP) shares increased 4.88% and closed at $1.72. The Company, on Mar. 2, announced the receipt of guidance from the Director of the Office of New Drugs at FDA which provides Chelsea a new regulatory path forward for Northera. This guidance has led us to a decision to resubmit a New Drug Application for Northera for the treatment of symptomatic neurogenic orthostatic hypotension which in turn has the potential to yield an approval decision by year-end.

How Should Investors Trade CHTP After The Recent Price movement? Find out Here

About ThePennyStockProfiler.com
ThePennyStockProfiler.com is engaged in providing the most up to date and useful information on Microcap Stocks poised to breakout. ThePennyStockProfiler.com also provides investors with trend analysis, detailed company profiles, and most importantly a much needed "informational edge" which can be used as a tool for making investment decisions. To Receive Instant updates in the inbox, readers are advised to sign up for free at http://www.ThePennyStockProfiler.com

Disclaimer
The assembled information disseminated by ThePennyStockProfiler.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. ThePennyStockProfiler.com does expect that investors will buy and sell securities based on information assembled and presented in phd-trading.com. PLEASE always do your own due diligence, and consult your financial advisor.